Hence, a higher frequency of CD44-/CD24- breast cancer cells, like higher frequency of CD44+/CD24- CSCs, was associated significantly with a shorter DFS in the training set of patients regardless of standard therapies. This evidence concerns the gene CD44 and breast carcinoma.